Modality
Gene Editing
MOA
TROP-2 ADC
Target
Menin
Pathway
Fibrosis
SCDWet AMD
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
~Nov 2020
→ ~Feb 2022
Phase 3
~May 2022
→ ~Aug 2023
NDA/BLA
Nov 2023
→ Aug 2030
NDA/BLACurrent
NCT07117255
12 pts·SCD
2024-04→2030-08·Recruiting
NCT04682268
2,259 pts·SCD
2023-11→2027-02·Active
2,271 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-1010mo awayPh3 Readout· SCD
2030-08-234.4y awayPh3 Readout· SCD
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Active
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-02-10 · 10mo away
SCD
Ph3 Readout
2030-08-23 · 4.4y away
SCD
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07117255 | NDA/BLA | SCD | Recruiting | 12 | Safety |
| NCT04682268 | NDA/BLA | SCD | Active | 2259 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Cevimavacamten | Denali | NDA/BLA | Menin | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 |